Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.38 |
| ▸ | CDK1 | P06493 | 6/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.38 |
| ▸ | GSK3A | P49840 | 6/20 | 0.38 |
| ▸ | GSK3B | P49841 | 6/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | INSR | P06213 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8875881 | 0.90 | GSK3B (0.44) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL4370028 | 0.86 | ADORA1 (0.41) | NOS2CDK1GSK3AGSK3BCDK2 | |
| SCHEMBL20197285 | 0.85 | GSK3A (0.42) | NOS2KDM4CCCNB2CDK1CCNB1 | |
| SCHEMBL8972110 | 0.82 | KDM4C (0.39) | KDM4CCCNB2CDK1CCNB1GSK3A | |
| SCHEMBL28836229 | 0.81 | CCR1 (0.34) | NOS2CCNB2CDK1CCNB1GSK3A | |
| SCHEMBL7832083 | 0.81 | KDM4E (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| Hydrochloric Acid SCHEMBL28836198 | 0.80 | CYP1A2 (0.35) | NOS2CCNB2CDK1CCNB1GSK3A | |
| SCHEMBL16544507 | 0.80 | KDM4C (0.38) | KDM4CCCNB2CDK1CCNB1GSK3A | |
| SCHEMBL3950341 | 0.79 | GSK3B (0.38) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL6317646 | 0.78 | LRRK2 (0.33) | CDK2PARP1PARP2CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-1988091-B1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-8242151-B2 | Tricyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1988091-A1 | TRICYCLIC COMPOUNDS | Kyowa Hakko Kogyo Co., Ltd (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-0480204-B1 | Imidazole derivatives, potent and selective antagonists of angiotensin II receptor | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5332744-A | Hypotensive, congestive heart failure, intraocular pressure | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| WO-1994011369-A1 | ANTIHYPERTENSIVE 5-[(IMIDAZO[4,5-b]PYRIDIN-3-YL)METHYL]BENZOFURAN DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-05-26 | — | — | WO | disclosed |
| US-5215994-A | Treating or preventing hypertension or heart failure | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| US-5210092-A | Hypotensive agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-11 | — | — | US | disclosed |
| US-5157026-A | Oxo-purines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0480204-A1 | Imidazole derivatives, potent and selective antagonists of angiotensin II receptor | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-5102880-A | Biphenyl imidazotriazine derivatives; Hypotensive and cardiotonic agents | MERCK & CO., INC. (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | NOS2 4681/4885KDM4C 3165/4885CCNB2 166/4885 |
| US-20090176760-A1 | TRICYCLIC COMPOUNDS | PPARG, PPARD, PPARA | NOS2 3349/4885KDM4C 1453/4885CCNB2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.